'S-HERTOGENBOSCH, The Netherlands, March 9 /PRNewswire/ -- PamGene International BV of 's-Hertogenbosch, The Netherlands, and Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), a division of Janssen Pharmaceutica NV of Beerse, Belgium, have announced significant progress in their kinase profiling collaboration. After extensive evaluation, PamGene's microarray-based biochemical kinase activity profiling and cellular inhibition assays will be further implemented in J&JPRD's research programs.
The evaluation program involved kinase inhibitor characterization on a panel of recombinant kinases. Additionally, a number of reference and J&JPRD proprietary kinase inhibitors were characterized in whole cell-based experiments. Kinase activity was measured by phosphorylation profiles (fingerprints) obtained from the kinetic readout from lysates of compound-treated cells.
About PamGene
PamGene was founded in 1999 in 's-Hertogenbosch, The Netherlands. Its 3-dimensional flow-through microarray technology is used for analysis of both proteins and nucleic acids. PamGene supports drug discovery in areas including compound profiling in diseases concerning, amongst others, kinases. Selectivity and potency data, quickly and easily generated on PamGene's PamStation(TM) instruments, enables pharmaceutical companies to select compounds with improved chances of success in drug development.
PamGene International BVCONTACT: For more information contact: PamGene International BV, MorvenBrodie, Communications Manager, PO Box 1345, 5200 BJ 's-Hertogenbosch, TheNetherlands, Tel.: +31-(0)73-6158-967, Fax: +31-(0)73-6158-081,mbrodie@pamgene.com
